880PSubgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. (23rd October 2018) - Procopio, G; Cognetti, F; Miceli, R; Milella, M; Mosca, A; Chiuri, V E; Bearz, A; Morelli, F; Ortega, C; Atzori, F; Passalacqua, R; Ratta, R; et al.